Publicaciones en colaboración con investigadores/as de Instituto de Investigaciones Biomédicas Alberto Sols (37)

2023

  1. Correction to: Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective (Cell & Bioscience, (2023), 13, 1, (44), 10.1186/s13578-023-00986-9)

    Cell and Bioscience

  2. Effect of rapamycin on lysosomal accumulation in a CRISPR/Cas9-based cellular model of VPS13A deficiency

    Journal of Cellular and Molecular Medicine, Vol. 27, Núm. 11, pp. 1557-1564

  3. Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

    Cell and Bioscience, Vol. 13, Núm. 1

  4. Pseudokinases, Tribbles Proteins and Cancer

    Cancers

2022

  1. FOXO transcription factors as therapeutic targets in human diseases

    Trends in Pharmacological Sciences, Vol. 43, Núm. 12, pp. 1070-1084

  2. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

    Journal of experimental & clinical cancer research : CR, Vol. 41, Núm. 1, pp. 285

2021

  1. A conserved ATG2 binding site in WIPI4 and yeast Hsv2 is disrupted by mutations causing β-propeller protein-associated neurodegeneration

    Human molecular genetics, Vol. 31, Núm. 1, pp. 111-121

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. The WIPI Gene Family and Neurodegenerative Diseases: Insights From Yeast and Dictyostelium Models

    Frontiers in Cell and Developmental Biology, Vol. 9

2020

  1. A novel reverse two-hybrid method for the identification of missense mutations that disrupt protein–protein binding

    Scientific Reports, Vol. 10, Núm. 1

  2. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

    Targeted Oncology, Vol. 15, Núm. 5, pp. 613-622

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2018

  1. The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca 2+ dysregulation, and mitochondrial abnormalities

    Journal of Neurochemistry, Vol. 145, Núm. 2, pp. 170-182

  2. Functional characterization of MODY2 mutations in the nuclear export signal of glucokinase

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 7, pp. 2385-2394

2017

  1. Heme-Oxygenase i and PCG-1α Regulate Mitochondrial Biogenesis via Microglial Activation of Alpha7 Nicotinic Acetylcholine Receptors Using PNU282987

    Antioxidants and Redox Signaling, Vol. 27, Núm. 2, pp. 93-105

  2. Mitochondrial complex I deactivation is related to superoxide production in acute hypoxia

    Redox Biology, Vol. 12, pp. 1040-1051

  3. Onconase dimerization through 3D domain swapping: Structural investigations and increase in the apoptotic effect in cancer cells*

    Biochemical Journal, Vol. 474, Núm. 22, pp. 3767-3781

  4. UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism

    Free Radical Biology and Medicine, Vol. 113, pp. 176-189

2016

  1. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

    Oncotarget, Vol. 7, Núm. 30, pp. 47565-47575